Phathom Pharmaceuticals, Inc. (PHAT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
100 Campus Drive
Florham Park, NJ 07932
United States of America (the)
Phone
877 742 8466
Sector
Healthcare
Industry
Biotechnology
Employees
427
First IPO Date
October 25, 2019
| Name | Title | Pay | Year Born |
| Steven L. Basta | Chief Executive Officer, President & Director | 1.17M | 1966 |
| Sanjeev Narula | Chief Financial & Business Officer | 644,285 | 1962 |
| Anne Marie Cook | Chief Legal Officer & Corporate Secretary | 663,406 | 1962 |
| David A. Socks | Co-Founder | 1.95M | 1975 |
| Azmi Nabulsi | Co-Founder | 1.95M | 1960 |
| Bill Aprea | Senior Vice President, Chief Compliance Officer & Deputy Chief Legal Officer | 0 | N/A |
| Eric Sciorilli | Director of Business Development & Investor Relations | 0 | N/A |
| Jonathan Bentley | Senior Vice President and Head of Sales, Operations & Training | 0 | N/A |
| Robert Breedlove | Vice President of Finance & Principal Accounting Officer | 0 | N/A |
| Nancy R. Phelan | Senior Vice President of Marketing & Analytics | 0 | 1969 |
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.